Take a look at our previous reports:

Consolidated statements of income and comprehensive income/loss (-)

(unaudited)

Consolidated income statement

 

Six months ended 30 June

(thousands of €, except per share data)

2024

2023(*)

Supply revenues

19,105

-

Collaboration revenues

121,200

118,627

Total net revenues

140,305

118,627

 

 

 

Cost of sales

(19,105)

-

Research and development expenses

(145,225)

(108,739)

Sales and marketing expenses

(7,092)

(1,434)

General and administrative expenses

(56,833)

(56,507)

Other operating income

16,638

20,348

Operating loss

(71,312)

(27,705)

 

 

 

Fair value adjustments and net currency exchange differences

49,455

183

Other financial income

50,015

33,723

Other financial expenses

(1,133)

(793)

Profit before tax

27,025

5,408

 

 

 

Income taxes

1,139

(12,732)

Net profit/loss (–) from continuing operations

28,164

(7,324)

 

 

 

Net profit from discontinued operations, net of tax

71,041

35,632

 

 

 

Net profit

99,205

28,308

 

 

 

Net profit attributable to:

 

 

Owners of the parent

99,205

28,308

Basic and diluted earnings per share

1.51

0.43

Basic and diluted earnings/loss (–) per share from continuing operations

0.43

(0.11)

(*)

The 2023 comparatives have been restated to consider the impact of classifying the Jyseleca® business as discontinued operations in 2023.

The accompanying notes form an integral part of these condensed consolidated financial statements.

Consolidated statement of comprehensive income/loss (–)

 

Six months ended 30 June

(thousands of €)

2024

2023(*)

Net profit

99,205

28,308

Items that will not be reclassified subsequently to profit or loss:

 

 

Re-measurement of defined benefit obligation

74

-

Fair value adjustment financial assets held at fair value through other comprehensive income

923

-

Items that may be reclassified subsequently to profit or loss:

 

 

Translation differences, arisen from translating foreign activities

215

256

Realization of translation differences upon sale of foreign operations

4,095

-

 

 

 

Other comprehensive income, net of income tax

5,307

28,564

 

 

 

Total comprehensive income attributable to:

 

 

Owners of the parent

104,512

28,564

 

 

 

Total comprehensive income attributable to owners of the parent arises from:

 

 

Continuing operations

29,112

(6,801)

Discontinued operations

75,400

35,365

Total comprehensive income, net of income tax

104,512

28,564

(*)

The 2023 comparatives have been restated to consider the impact of classifying the Jyseleca® business as discontinued operations in 2023.

The accompanying notes form an integral part of these condensed consolidated financial statements.